Tirzepatide for Obesity Treatment and Diabetes Prevention
Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity
Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor Agonists
Association between plausible genetic factors and weight loss from GLP1-RA and bariatric surgery
Cagrilintideâ€“Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes: The OASIS 2 Randomized Clinical Trial
Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency
Clinical features modifying the cardiovascular benefits of GLP-1 receptor agonists: a systematic review and meta-analysis
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
